Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsPraful bohra

    Praful Bohra

    Jump to

    • Not positive on Lupin's US business: Surajit Pal

      Lupin on Wednesday received preliminary approval from the US FDA to market a generic equivalent of GlaxoSmithKline Plc‘s ViiV Healthcare‘s (ViiV) antiretroviral (ARV) Lexiva tablets in 700 milligram dosage form. This product was filed from the company's Goa plant which has run into a problem with the US FDA

    • HC ban won't hurt Glenmark; target Rs 1370: Religare Ent

      Praful Bohra, Ananlyst, Religare Enterprises says this is not “an incrementally negative news” because sales of this drug have already been halted.

    • What took mighty Lupin down!

      In an interview with CNBC-TV18‘s Sonia Shenoy & Latha Venkatesh, Praful Bohra, VP- Research, Religare said that Lupin‘s numbers are weak due to decline in the US business.

    • Praful Bohra explains how Nirmal Bang plays pharma stocks

      Praful Bohra of Nirmal Bang Institutional Equities feels Lupin‘s deal with Merck Serano will help the former to make way into incremental markets. Further, he has a positive call on the stock, as he believes recent initiatives taken by the pharma major will be beneficial for business in medium term.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347